No information available. |
Summary of Clinical Use |
Secukinumab is approved by the US FDA for the treatment of plaque psoriasis. Secukinumab also met its clinical endpoints in Phase 2I clinical trial for ankylosing spondylitis (NCT01649375) [1], and was FDA approved for this indication and psoriatic arthritis [7-8] in January 2016. The antibody is also in Phase 2 clinical trial for multiple sclerosis (NCT01874340) based on results from experiments in an animal model of the disease (experimental autoimmune encephalomyelitis, EAE) and in vitro human cell assays [3]. |
Mechanism Of Action and Pharmacodynamic Effects |
Secukinumab targets proinflammatory interleukin (IL)-17A [5] which is released by T helper 17 cells [11], and is a validated molecular target for the treatment of chronic immune diseases [10]. Antibody neutralisation of circulating IL-17A reduces symptoms in autoimmune diseases such as plaque psoriasis [6,9], rheumatoid arthritis (note that clinical trial results have not shown significant improvement over placebo [4]), and chronic noninfectious uveitis. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |